Episode 58: CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN) with Dr. Piers Blombery

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/ec/ff/29/ecff295f-8f4c-e8f2-8d5c-0c8a88cb945e/mza_11191508321578000071.jpg/600x600bb.jpg

Blood Cancer Talks

Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

67 episodes

1 month ago

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

All content for Blood Cancer Talks is the property of Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Education

Health & Fitness,

Medicine

Episode 58: CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN) with Dr. Piers Blombery

Blood Cancer Talks

50 minutes

7 months ago

Episode 58: CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN) with Dr. Piers Blombery

In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric antigen receptor following cilta-cel treatment for multiple myeloma. As a bonus, we also briefly discussed Dr. Blombery’s paper on menin inhibitors in UBTF tandem duplicated AML. Here are the papers we discussed:

1. CTTLN cases from CARTITUDE-4: https://pubmed.ncbi.nlm.nih.gov/39938094/

2. CTTLN case from MSKCC with insertional mutagenesis: https://pubmed.ncbi.nlm.nih.gov/39908432/

3. Other CTTLN cases in myeloma:
https://pubmed.ncbi.nlm.nih.gov/38865661/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8417502/

4. Response and resistance to menin inhibitors in UBTF tandem duplication AML: https://pubmed.ncbi.nlm.nih.gov/38924737/